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Physical activity and prevention of Alzheimer’s disease
Alzheimer’s disease (AD) is an irreversible, progressive
brain disorder that affects about 48 million people worldwide
and is the cause of 60%–70% of dementia, particularly in
people over 65 years old. Without prevention or treatment, the
disease slowly destroys memory and thinking skills and, even-
tually, the individual loses the ability to carry out the simplest
tasks. Unfortunately, there is no drug available to stop or reverse
the progress of AD so far. Although 70% of the risk of AD is
believed to be genetic, recent studies found that environmental
and lifestyle factors may play a role in the development and
course of AD and that physical activity might help to reduce the
risk of cognitive decline of AD. In this special section, we
invited 5 world-recognized clinical and basic scientists who
specialize in AD studies to present the most recent discoveries:
biomarkers for AD (Hampel et al.1), the newest drug develop-
ment (Vassar2), potential anti-Tau therapy (Takashima3),
microbiome as a novel therapeutic approach (Lukiw4), and
exercise in the prevention of AD (Shen and Li5).
AD does not occur in 1 day; it develops slowly from mild to
moderate to severe over many years. Indeed, the initial symp-
toms of AD are often confused with normal aging, such as
wandering, getting lost, repeating questions, and taking longer
to complete normal daily tasks, as well as personality and
behavior changes. Identifying the early stage of AD and devel-
oping prevention tools to stop or slow the progress of the
disease are critical. The biomarkers for AD diagnosis at an early
stage will provide objective and reliable measures of disease
progress. Dr. Hampel is an internationally recognized leader in
the discovery of biomarkers for AD. In his manuscript entitled
“Biomarker-guided classification scheme of neurodegenerative
diseases”, he and his colleagues presented an unbiased descrip-
tive classification system for neurodegenerative dementia,
including AD, and clinical and biomarker information.1 Such
important information would allow the characterization and
identification of AD even at the earliest asymptomatic preclini-
cal stage through population-based screening.
Although there is no drug that can stop or prevent AD, there
are several therapeutic candidates that have been actively devel-
oped over the past few years, including inhibitor of beta
secretase (BACE). BACE is a key enzyme for cleaving amyloid
precursor protein, a major protein associated with AD. Blocking
BACE in animal models showed a great effect in reducing AD
pathologic changes. Dr. Vassar is one of the 4 scientist groups
who first discovered BACE in 1999, when his discovery was
published in Science;6 the other 3 groups published in Nature7,8
and Molecular and Cellular Neuroscience9 at the same time.
Since then, Dr. Vassar has been working on BACE as the best
and most possible drug for AD. In his article entitled “BACE1
inhibition as a therapeutic strategy for Alzheimer disease” we
learn the most current information on drug discovery using
BACE inhibitors from animal to clinical trials.2
Another major pathologic feature of AD is Tau protein,
which forms special twisted strands as tangles and destroys
neurons in the brain. Understanding how Tau protein causes AD
and developing anti-Tau therapy have been the major focus of
Dr. Takashima’s research.3 In his paper entitled “Mechanism of
neurodegeneration through Tau and therapy for Alzheimer’s
disease”, he explains his studies on Tau in AD and offers novel
insights about Tau aggregation pathology, particularly suggest-
ing that inhibition of Tau aggregation might be a promising
option for blocking AD progression.
“From gut to brain” is a new discovery and a novel approach
for AD research. Increasing evidence indicates that the human
microbiome may contribute to the regulation of the communi-
cation between the gastrointestinal (GI) tract and the central
nervous system. Studies of AD demonstrated that dysregulation
of microbiomes in the GI tract could be associated with the
progression of AD and that “good gut bacteria” may delay
AD-associated cognitive impairment. Dr. Lukiw was one of the
scientists who first reported the microbial-neuronal interaction
inAD.10 In his short article entitled “The microbiome, microbial-
generated proinflammatory neurotoxins, and Alzheimer’s
disease”, we learn about the most recent publications on the
potential contribution of microbiome-generated factors in
proinflammatory signaling in the brain as well as the recent
recognition of the beneficial effects of dietary fibers on the
human GI tract microbiome, with specific reference to AD
neuropathology.4
Finally, we would like to know whether exercise can prevent,
stop, or reverse AD. During the past decades, extensive studies
have demonstrated that exercise is good and important for
people with AD, particularly for reducing some of the AD
symptoms. In general, exercise may help elderly people to
sleep, lower their anxiety level, and prevent falls. Interestingly,
recent studies found that exercise or regular physical activity
might also play a role in AD. Dr. Shen is a world-recognized AD
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exercise and AD. In his article entitled “What do we know from
clinical trials on exercise and Alzheimer’s disease?” he gath-
ered the findings from the most current clinical trials on exer-
cise in AD and focused on the effects of physical exercise,
cognitive stimulation, and a combination of both physical and
cognitive training on protection and rescue from cognitive
decline in people with AD.5
Together, we are very lucky and excited to have a group of
outstanding scientists from around the world to share their most
recent discoveries or visions on AD research and the potential
of exercise intervention in prevention and treatment of this
disease. We hope that this special section of the Journal of Sport
and Health Science will not only provide our readers with a
view of AD but also open a new window to search for future
approaches to using exercise to stop and treat the disease.
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